NASDAQ$GPCR

Structure Therapeutics Inc · Q4 2026 earnings

Q4 2026 earnings · · After market close · Investor relations

Reports awaiting report

Structure Therapeutics hasn't published Q4 2026 actuals yet. The tiles below frame what to compare against; sections further down are historical context only.

  • Most recent report

    Q3 2025

    Revenue
    $5M
    EPS
    -$0.37
  • FY2026 consensus

    Analyst consensus

    Revenue
    $0.00
    EPS
    -$1.48

Revenue & EPS history

Structure Therapeutics · Revenue · Quarterly

$5M

Q3 2025

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 15 quarterly earnings reports · overlaid with Q4 2026

Historical avgQ4 2026

+1.2%

Avg return

Earnings day

-1.1%

Avg return

5 days after

+9.8%

Avg return

30 days after

40%

6 / 15 earnings

Positive

+14.8%

Q4 2024

Best reaction

-11.6%

Q3 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2026-2.6%-2.5%-29.1%
Q3 2025-2.0%+7.3%+3.3%
Q1 2025-4.6%-11.2%-21.2%
Q4 2024+14.8%+13.1%-0.6%
Q3 2024+1.9%-14.1%-15.5%
Q2 2024-0.8%+0.9%+8.6%
Q1 2024-8.7%-9.0%+35.3%
Q4 2023-2.5%-5.9%+15.1%
Q3 2022+11.5%+7.1%+23.4%
Q3 2023-11.6%-1.6%+7.2%
Q2 2023-1.9%-2.9%-0.1%
Q2 2022-1.9%-2.9%-0.1%
Q1 2023+8.9%+1.9%+40.2%
Q4 2022+8.9%+1.9%+40.2%
Q1 2022+8.9%+1.9%+40.2%
Q4 2021

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro